ACADIA Pharmaceuticals Inc. filed its quarterly report on Form 10-Q with the SEC on November 5, 2026, covering the fiscal quarter and nine-month period ended September 30, 2026.

Key Highlights

  • Net product sales of $342.3 million for the third quarter of 2026, up from $278.6 million in the same quarter of 2025, according to the filing.
  • Nine-month net income of $88.7 million ($0.51 diluted earnings per share), compared with $117.4 million ($0.69 diluted EPS) for the nine months ended September 30, 2025.
  • Third-quarter net income of $53.5 million ($0.31 diluted EPS), versus $71.8 million ($0.42 diluted EPS) in the prior-year quarter.
  • Total assets of $1.794 billion as of September 30, 2026, compared with $1.564 billion at December 31, 2025.
  • Cash and cash equivalents of $322.4 million at September 30, 2026, up from $177.7 million at December 31, 2025.
  • 172,789,550 shares of common stock issued and outstanding as of September 30, 2026, per the filing.
  • Accumulated deficit narrowed to $1.724 billion at September 30, 2026, from $1.813 billion at December 31, 2025.

ACADIA Pharmaceuticals Financial Results: Third Quarter and Nine Months Ended September 30, 2026

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a large accelerated filer incorporated in Delaware and headquartered in San Diego, California, reported total revenues of $342.3 million for the three months ended September 30, 2026, consisting entirely of net product sales, according to the filing. This compares with $278.6 million in net product sales for the same period in 2025. For the nine months ended September 30, 2026, net product sales totaled $918.3 million, up from $787.5 million in the comparable 2025 period.

The company disclosed total operating expenses of $270.6 million for the third quarter of 2026, including cost of product sales of $35.1 million, research and development expenses of $76.3 million, and selling, general and administrative expenses of $159.2 million. Income from operations for the quarter was $71.7 million. Income tax expense of $26.9 million was recorded in the quarter, contrasting with an income tax benefit of $27.2 million in the third quarter of 2025, contributing to the year-over-year decline in net income despite higher revenue. For the nine-month period, total operating expenses were $813.4 million and income from operations was $104.9 million.

The condensed consolidated balance sheet as of September 30, 2026, reflected total stockholders' equity of $1.387 billion, compared with $1.227 billion at December 31, 2025. Investment securities classified as available-for-sale stood at $654.1 million. Net cash provided by operating activities for the nine months ended September 30, 2026, was $146.3 million. The filing also disclosed an accrued milestone and contingent payment in connection with an asset acquisition of $35.0 million as a noncash item for the nine-month period.

What Was Disclosed

ACADIA Pharmaceuticals filed its Form 10-Q for the quarter ended September 30, 2026, reporting nine-month net income of $88.7 million on net product sales of $918.3 million, with total assets of $1.794 billion and 172,789,550 shares outstanding.